25 June 2025
25 June 2025
Dupixent's approval was based on findings from the ADEPT Phase II/III trial.
Royalty's commitment involves tiered royalties for 15 years on global net sales of daraxonrasib.
The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.
The total deal value of innovator drug acquisitions rose 780% between 2022 and 2024.
The drug's launch into the Chinese market follows Phase I and Phase III studies.
The collaboration will use Novoheart's mini-Heart Platform, which includes 3D bioengineered cardiac tissues.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
